A calcium-sensitive promoter construct for gene therapy

Gene Therapy

Volumn 20, Issue 3, 2013, Pages 248-254

  Merlet, E ^a,b   Lipskaia, L ^a,b   Marchand, A ^a,b   Hadri, L ^a,b   Mougenot, N ^a,b   Atassi, F ^a,b   Liang, L ^a,b   Hatem, S N ^a,b   Hajjar, R J ^a,b   Lompre A M ^a,b  

^a Sorbonne Universités   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CALCIUM ION; CYCLOSPORIN A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; THAPSIGARGIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENDOPLASMIC RETICULUM; GENE CONSTRUCT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; RAT; RECEPTOR UPREGULATION; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSGENE; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CALCIUM; CAROTID ARTERY INJURIES; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA; CYTOMEGALOVIRUS; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LUCIFERASES; MALE; MICROSCOPY, CONFOCAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; RATS; RATS, WISTAR; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SERUM;

CYTOMEGALOVIRUS; RATTUS;

EID: 84874785360     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.30     Document Type: Article

References (35)

1. Lipskaia L, Hulot JS, Lompre AM. Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pflugers Arch 2009; 457: 673-685.
2. Lompre AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation 2010; 121: 822-830.
3. House SJ, Potier M, Bisaillon J, Singer HA, Trebak M. The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch 2008; 456: 769-785.
4. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011; 477: 601-605.
5. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
6. Aubart FC, Sassi Y, Coulombe A, Mougenot N, Vrignaud C, Leprince P et al. RNA interference targeting STIM1 suppresses vascular smooth muscle cell proliferation and neointima formation in the rat. Mol Ther 2009; 17: 455-462.
7. Lipskaia L, del Monte F, Capiod T, Yacoubi S, Hadri L, Hours M et al. Sarco/ endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 2005; 97: 488-495.
8. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
9. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurinmediated cardiac hypertrophic growth. Mol Cell Biol 2002; 22: 7603-7613.
10. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol 2002; 541: 1-8.
11. Lipskaia L, Pourci ML, Delome'nie C, Combettes L, Goudouneche D, Paul JL et al. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res 2003; 92: 1115-1122.
12. Gwack Y, Feske S, Srikanth S, Hogan PG, Rao A. Signalling to transcription: storeoperated Ca2+ entry and NFAT activation in lymphocytes. Cell Calcium 2007; 42: 145-156.
13. Lipskaia L, Lompre AM. Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation. Biol Cell 2004; 96: 55-68.
14. Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009; 9: 810-820.
15. Muller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010; 10: 645-656.
16. Szymanski P, Anwer K, Sullivan SM. Development and characterization of a synthetic promoter for selective expression in proliferating endothelial cells. J Gene Med 2006; 8: 514-523.
17. Pacak CA, Byrne BJ. AAV Vectors for Cardiac Gene Transfer: Experimental Tools and Clinical Opportunities. Mol Ther 2011; 19: 1582-1590.
18. Vallot O, Combettes L, Jourdon P, Inamo J, Marty I, Claret M et al. Intracellular Ca(2+) handling in vascular smooth muscle cells is affected by proliferation. Arterioscler Thromb Vasc Biol 2000; 20: 1225-1235.
19. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004; 94: 110-118.
20. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 2006; 116: 3114-3126.
21. Nakayama H, Otsu K, Yamaguchi O, Nishida K, Date MO, Hongo K et al. Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 2003; 17: 61-63.
22. Bobe R, Hadri L, Lopez JJ, Sassi Y, Atassi F, Karakikes I et al. SERCA2a controls the mode of agonist-induced intracellular Ca(2+) signal, transcription factor NFAT and proliferation in human vascular smooth muscle cells. J Mol Cell Cardiol 2011; 50: 621-633.
23. Hulot JS, Fauconnier J, Ramanujam D, Chaanine A, Aubart F, Sassi Y et al. Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation 2011; 124: 796-805.
24. Zhang W, Halligan KE, Zhang X, Bisaillon JM, Gonzalez-Cobos JC, Motiani RK et al. Orai1-mediated ICRAC is essential for neointima formation after vascular injury. Circ Res 2011; 109: 534-542.
25. del Monte F, Hajjar RJ, Harding SE. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res 2001; 88: E66-E67.
26. Miyazaki M, Fujikawa Y, Takita C, Tsumura H. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 2007; 26: 231-239.
27. Thomas TP, Patri AK, Myc A, Myaing MT, Ye JY, Norris TB et al. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 2004; 5: 2269-2274.
28. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
29. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53.
30. Koerber JT, Jang JH, Schaffer DV. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008; 16: 1703-1709.
31. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004; 109: 513-519.
32. Su H, Arakawa-Hoyt J, Kan YW. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA 2002; 99: 9480-9485.
33. Su H, Huang Y, Barcena A, Arakawa-Hoyt J, Grossman W, Kan YW. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci USA 2004; 101: 16280-16285.
34. Eggermont JA, Wuytack F, Verbist J, Casteels R. Expression of endoplasmicreticulum Ca2(+)-pump isoforms and of phospholamban in pig smooth-muscle tissues. Biochem J 1990; 271: 649-653.
35. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100: 2308-2311.